Financial Gravity Asset Management, Inc. Ligand Pharmaceuticals Inc Transaction History

Financial Gravity Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$113.03 - $155.64 $2,373 - $3,268	-21 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$99.52 - $215.83 $2,089 - $4,532	21 New	21 $3.14 Million
Q2 2020 Aug 13, 2020	SELL	$68.28 - $123.65 $273 - $494	-4 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$63.37 - $107.88 $316 - $539	-5 Reduced 55.56%	4 $0
Q2 2019 Jul 26, 2019	SELL	$107.38 - $129.34 $42,844 - $51,606	-399 Reduced 97.79%	9 $1,000
Q1 2019 Apr 19, 2019	BUY	$105.93 - $142.47 $22,139 - $29,776	209 Added 105.03%	408 $51,000
Q3 2018 Oct 31, 2018	BUY	$211.18 - $274.49 $39,913 - $51,878	189 Added 1890.0%	199 $33,000
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $452 - $623	3 Added 42.86%	10 $2,000
Q1 2018 May 23, 2018	BUY	$138.63 - $182.62 $970 - $1,278	7 New	7 $1,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.